Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 1
1989 1
1990 2
1991 4
1992 1
1996 1
1997 2
1998 6
2000 3
2001 1
2003 3
2004 1
2005 1
2006 3
2007 2
2008 4
2009 7
2010 8
2011 5
2012 4
2013 1
2014 3
2017 2
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

65 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Quintás-Cardama A, et al. Among authors: scherle pa. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. Blood. 2010. PMID: 20130243 Free PMC article.
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. doi: 10.1158/1078-0432.CCR-11-1157. Epub 2011 Sep 14. Clin Cancer Res. 2011. PMID: 21918175 Free article.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K. Fridman JS, et al. Among authors: scherle pa. J Immunol. 2010 May 1;184(9):5298-307. doi: 10.4049/jimmunol.0902819. Epub 2010 Apr 2. J Immunol. 2010. PMID: 20363976 Free article.
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Blood. 2010 Apr 29;115(17):3520-30. doi: 10.1182/blood-2009-09-246124. Epub 2010 Mar 2. Blood. 2010. PMID: 20197554 Free article.
Development of c-MET pathway inhibitors.
Liu X, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2011 Sep;20(9):1225-41. doi: 10.1517/13543784.2011.600687. Epub 2011 Jul 11. Expert Opin Investig Drugs. 2011. PMID: 21740293 Review.
ADAM proteases, ErbB pathways and cancer.
Zhou BB, Fridman JS, Liu X, Friedman SM, Newton RC, Scherle PA. Zhou BB, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2005 Jun;14(6):591-606. doi: 10.1517/13543784.14.6.591. Expert Opin Investig Drugs. 2005. PMID: 16004590 Review.
Targeting the c-MET signaling pathway for cancer therapy.
Liu X, Yao W, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2008 Jul;17(7):997-1011. doi: 10.1517/13543784.17.7.997. Expert Opin Investig Drugs. 2008. PMID: 18549337 Review.
65 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page